Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Rottenberg

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
Nature Communications|May 24, 2024
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumoursDiego Dibitetto, Martin Liptay, Francesca Vivalda, et al.
NPJ Precision Oncology|July 11, 2026
Aurora kinase A is a synthetic lethal target in FANCA-deficient cancersDilara Akhoundova, Martín González-Fernández, Aavash Baral, et al.
Science (New York, N.Y.)|February 19, 2026
The oncogenome of the domestic catBailey A Francis, Latasha Ludwig, Chang He, et al.
Nature|March 25, 2015
REV7 counteracts DNA double-strand break resection and affects PARP inhibitionGuotai Xu, J Ross Chapman, Inger Brandsma, et al.
Cancer Cell|June 13, 2018
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic LethalityEwa Gogola, Alexandra A Duarte, Julian R de Ruiter, et al.
Cancer Cell|June 12, 2019
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic LethalityEwa Gogola, Alexandra A Duarte, Julian R de Ruiter, et al.
The Journal of Clinical Investigation|July 26, 2016
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1Rinske Drost, Kiranjit K Dhillon, Hanneke van der Gulden, et al.
Cell|December 12, 2017
A Living Biobank of Breast Cancer Organoids Captures Disease HeterogeneityNorman Sachs, Joep de Ligt, Oded Kopper, et al.
Nature|July 20, 2018
The shieldin complex mediates 53BP1-dependent DNA repairSylvie M Noordermeer, Salomé Adam, Dheva Setiaputra, et al.
Nature|September 1, 2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Nature Communications|May 24, 2024
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumoursDiego Dibitetto, Martin Liptay, Francesca Vivalda, et al.
NPJ Precision Oncology|July 11, 2026
Aurora kinase A is a synthetic lethal target in FANCA-deficient cancersDilara Akhoundova, Martín González-Fernández, Aavash Baral, et al.
Science (New York, N.Y.)|February 19, 2026
The oncogenome of the domestic catBailey A Francis, Latasha Ludwig, Chang He, et al.
Nature|March 25, 2015
REV7 counteracts DNA double-strand break resection and affects PARP inhibitionGuotai Xu, J Ross Chapman, Inger Brandsma, et al.
Cancer Cell|June 13, 2018
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic LethalityEwa Gogola, Alexandra A Duarte, Julian R de Ruiter, et al.
Cancer Cell|June 12, 2019
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic LethalityEwa Gogola, Alexandra A Duarte, Julian R de Ruiter, et al.
The Journal of Clinical Investigation|July 26, 2016
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1Rinske Drost, Kiranjit K Dhillon, Hanneke van der Gulden, et al.
Cell|December 12, 2017
A Living Biobank of Breast Cancer Organoids Captures Disease HeterogeneityNorman Sachs, Joep de Ligt, Oded Kopper, et al.
Nature|July 20, 2018
The shieldin complex mediates 53BP1-dependent DNA repairSylvie M Noordermeer, Salomé Adam, Dheva Setiaputra, et al.
Nature|September 1, 2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Pageof 13